Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Hester Biosciences Ltd

HESTERBIO

Hester Biosciences Ltd

HESTERBIO
Health CareBiotechnology
SmallcapWith a market cap of ₹2,250 cr, stock is ranked 1,063
High RiskStock is 3.33x as volatile as Nifty
2,645.6010.91% (+260.15)
2,645.6010.91% (+260.15)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareBiotechnology
SmallcapWith a market cap of ₹2,250 cr, stock is ranked 1,063
High RiskStock is 3.33x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareBiotechnology
SmallcapWith a market cap of ₹2,250 cr, stock is ranked 1,063
High RiskStock is 3.33x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
95.977.430.23%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.626.470.53%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Hester Biosciences Limited is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 11.53%, vs industry avg of 19.21%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 2.68% to 1.92%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -14.6%, vs industry avg of 1.42%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue101.77123.53138.49185.28189.64219.01249.17285.65319.80323.90
Raw Materialssubtract22.5329.1135.3941.9244.1546.6375.4182.7487.14249.31
Power & Fuel Costsubtract5.815.596.377.838.137.5710.2812.7415.30
Employee Costsubtract15.4418.3223.2428.9340.6538.9245.3356.0264.13
Selling & Administrative Expensessubtract13.5515.9317.9224.9937.7835.4740.1854.7756.48
Operating & Other expensessubtract10.1813.155.756.36-2.8520.413.829.2227.85
Depreciation/Amortizationsubtract5.757.009.6611.7613.0713.3116.5820.7017.1715.82
Interest & Other Itemssubtract3.723.504.046.637.376.604.069.3219.7820.03
Taxes & Other Itemssubtract5.627.3810.5115.2912.1615.6814.1713.5313.0715.29
EPS22.5327.6830.1148.8734.3040.4646.2531.2822.1927.57
DPS4.105.3010.0011.006.6010.0010.008.006.006.00
Payout ratio0.180.190.330.230.190.250.220.260.270.22
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Hester Biosciences Ltd119.207.430.23%
Biocon Ltd39.401.590.15%
Panacea Biotec Ltd-2,231.203.09—
Zenotech Laboratories Ltd54.955.03—

Price Comparison

Compare HESTERBIO with any stock or ETF
Compare HESTERBIO with any stock or ETF
HESTERBIO
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding53.73%0.00%0.02%0.61%45.64%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.45%0.42%0.43%0.43%0.52%0.61%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Hester Biosciences Ltd

Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0006%0.07%0.07%82/102 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

HESTERBIO has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.25%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.52 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 22, 2024

Final
Final | Div/Share: ₹6.00

Dividend/Share

₹6.00

Ex DateEx Date

Aug 22, 2024

Cash Dividend

Ex DateEx DateSep 13, 2023

Final
Final | Div/Share: ₹8.00

Dividend/Share

₹8.00

Ex DateEx Date

Sep 13, 2023

Cash Dividend

Ex DateEx DateAug 11, 2022

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Aug 11, 2022

Cash Dividend

Ex DateEx DateAug 5, 2021

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Aug 5, 2021

Cash Dividend

Ex DateEx DateAug 27, 2020

Final
Final | Div/Share: ₹6.60

Dividend/Share

₹6.60

Ex DateEx Date

Aug 27, 2020

News & Opinions
Earnings
Hester Biosciences consolidated net profit rises 100.49% in the September 2024 quarter

Net profit of Hester Biosciences rose 100.49% to Rs 8.20 crore in the quarter ended September 2024 as against Rs 4.09 crore during the previous quarter ended September 2023. Sales rose 18.78% to Rs 83.69 crore in the quarter ended September 2024 as against Rs 70.46 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.6970.46 19 OPM %22.8918.75 - PBDT16.0711.05 45 PBT11.876.76 76 NP8.204.09 100 Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Hester Biosciences announces board meeting date

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 8.01% in the June 2024 quarter

Net profit of Hester Biosciences rose 8.01% to Rs 6.34 crore in the quarter ended June 2024 as against Rs 5.87 crore during the previous quarter ended June 2023. Sales declined 6.35% to Rs 82.27 crore in the quarter ended June 2024 as against Rs 87.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales82.2787.85 -6 OPM %21.4516.35 - PBDT14.7314.31 3 PBT10.598.91 19 NP6.345.87 8 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Hester Biosciences to hold AGM

Hester Biosciences announced that the Annual General Meeting (AGM) of the company will be held on 29 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Hester Biosciences schedules board meeting

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Hester Biosciences Ltd leads gainers in ‘B’ group

5 months agoBusiness Standard

Hester Biosciences to repurpose BSL-3 facility as Covid vaccine demand tapers off

1 year agoThe Hindu Businessline

Hester Biosciences to develop inactivated influenza vaccine for poultry

1 year agoThe Hindu Businessline

HesterBio gains on acquiring technology for H9N2 avian influenza virus vaccine from ICAR - NIHSAD

1 year agoBusiness Standard

Hold Hester Biosciences; target of Rs 2070: ICICI Direct

2 years agoMoneycontrol